{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T17:58:10Z","timestamp":1791482290297,"version":"4.3.4"},"reference-count":28,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2011,7,13]],"date-time":"2011-07-13T00:00:00Z","timestamp":1310515200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Geriat Psychiatry"],"published-print":{"date-parts":[[2012,5]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>The aim of this study was to assess the short\u2010term tolerability of two titration schedules of sublingual asenapine in older patients with psychosis, not associated with organic brain disease, and to compare asenapine pharmacokinetics in older patients versus younger adults with schizophrenia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients \u226565\u2009years with psychosis without dementia were randomized for 6\u2009weeks to two dose\u2010escalation regimens: 2\u2009days at 2\u2009mg twice daily (BID), 2\u2009days at 5\u2009mg BID, and 10\u2009mg BID thereafter (slow escalation); or 4\u2009days at 5\u2009mg BID and 10\u2009mg BID thereafter (rapid escalation). Clinical and pharmacokinetic assessments were performed in each group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 122 randomized patients, 76 (62.3%) completed the trial. The incidence of treatment\u2010emergent adverse events (AEs) was comparable (72.1%) with both regimens. The most frequently reported AEs were hypertension, headache, and somnolence; incidence of extrapyramidal symptom\u2013related AEs was 5.7%. Mean end point weight change was 0.4\u2009kg. For asenapine 5 and 10\u2009mg BID, median times to maximum concentration were 1.00 and 1.06\u2009h, respectively; maximum concentrations (<jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub>) were 4.73 and 7.93\u2009ng\/mL; areas under the concentration versus time curve (0\u201312\u2009h; <jats:italic>AUC<\/jats:italic><jats:sub>0\u221212<\/jats:sub>) were 32.1 and 56.3\u2009ng\u2219h\/mL.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Despite 12\u201330% increases in asenapine <jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub> and <jats:italic>AUC<\/jats:italic><jats:sub>0\u221212<\/jats:sub> in older patients compared with previously published findings in younger schizophrenia patients, possibly as a result of slower drug clearance, asenapine was generally well tolerated during both dose\u2010escalation schedules. No dose adjustment appears to be necessary in older patients. Copyright \u00a9 2011 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/gps.2737","type":"journal-article","created":{"date-parts":[[2011,7,14]],"date-time":"2011-07-14T02:15:26Z","timestamp":1310609726000},"page":"472-482","source":"Crossref","is-referenced-by-count":17,"title":["Short\u2010term safety and pharmacokinetic profile of asenapine in older patients with psychosis"],"prefix":"10.1002","volume":"27","author":[{"given":"Steven L.","family":"Dubovsky","sequence":"first","affiliation":[{"name":"University at Buffalo  Buffalo NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen","family":"Frobose","sequence":"additional","affiliation":[{"name":"Merck  Rahway NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Phiri","sequence":"additional","affiliation":[{"name":"Merck  Rahway NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rik","family":"de Greef","sequence":"additional","affiliation":[{"name":"Merck Sharp &amp; Dohme  Oss Noord\u2010Brabant The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Panagides","sequence":"additional","affiliation":[{"name":"Merck &amp; Co, Inc  Summit NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,7,13]]},"reference":[{"key":"e_1_2_8_2_1","unstructured":"European Medicines Agency.Sycrest (asenapine). Available at:http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/001177\/human_med_001379.jsp&murl=menus\/medicines\/medicines.jsp&mid=WC0b01ac058001d124&jsenabled=true. [accessed on 28 September2010a]."},{"key":"e_1_2_8_3_1","unstructured":"Saphris\u00ae(asenapine sublingual tablets). Full Prescribing Information Schering Corporation a subsidiary ofMerck & Co. Inc Whitehouse Station NJ 2010b."},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0278-5846(01)00322-0"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270009344855"},{"key":"e_1_2_8_6_1","unstructured":"DogteromP TimmerC deGreefR et al. A phase I study to investigate the safety tolerability and pharmacokinetics of single and multiple doses of sublingually administered asenapine in healthy male volunteers. Presented at:American Society for Clinical Pharmacology and Therapeutics 110th Annual Meeting; 3\u20138 May2009; Washington DC."},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.a1227"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200623120-00002"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.38330.470486.8F"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.161.6.1113"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0749-0690(03)00042-9"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.56.9.848"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3181d35d6b"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/03602530902722679"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/gps.1184"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2009.00748.x"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2009.00749.x"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2009.12.028"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v68n1004"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-977X(09)70863-6"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/gps.1358"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1988.01800350011002"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1992.203"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurpsy.2008.10.005"},{"key":"e_1_2_8_25_1","first-page":"819","article-title":"Olanzapine therapy in elderly patients with schizophrenia","volume":"34","author":"Sajatovic M","year":"1998","journal-title":"Psychopharmacol Bull"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0030-1248313"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(00)80085-5"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/JGP.0b013e31815a3e7a"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.08r04171"}],"container-title":["International Journal of Geriatric Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fgps.2737","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/gps.2737","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T12:13:29Z","timestamp":1700568809000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/gps.2737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7,13]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["10.1002\/gps.2737"],"URL":"https:\/\/doi.org\/10.1002\/gps.2737","archive":["Portico"],"relation":{},"ISSN":["0885-6230","1099-1166"],"issn-type":[{"value":"0885-6230","type":"print"},{"value":"1099-1166","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7,13]]}}}